IMRICOR Q3 CY2026 QUARTERLY ACTIVITIES REPORT AND FORM 10-Q SUBMISSION Key Highlights U.S. Commercial Launch • U.S. commercial launch commenced, with Rady Children’s Hospital–San Diego becoming Imricor’s first commercial U.S. hospital customer, purchasing NorthStar to establish the...
Q3 CY2026 Quarterly Activities Report & Form 10-Q Submission
Filed with ASX · · 7 pages · English
Summary by 6ix AI
The report highlights the commencement of the U.S. commercial launch, with significant sales to leading children's hospitals for radiation-free cardiac procedures. Financially, the company reported revenue growth attributed to initial U.S. sales, with total cash holdings noted at a substantial amount.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Imricor Medical Systems, Inc. on 6ix
In the deck
Story so far
Earlier from Imricor Medical Systems
- Q3 FY26 Results Webinar Notification
- Notification of cessation of securities - IMR
- Notification regarding unquoted securities - IMR
- FDA Completes Review of Third PMA Module
- Cleansing Notice
Later from Imricor Medical Systems
All Imricor Medical Systems news releasesFollow Imricor Medical Systems into a list and get an email when it puts out news.
Follow Imricor Medical Systems